Filing Details
- Accession Number:
- 0001209191-15-054396
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-17 20:19:29
- Reporting Period:
- 2014-06-25
- Filing Date:
- 2015-06-17
- Accepted Time:
- 2015-06-17 19:19:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1510580 | Kite Pharma Inc. | KITE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610823 | Jeffrey Wiezorek | C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404 | Vp Clinical Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-06-25 | 4,000 | $17.00 | 5,218 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2015-06-15 | 9,000 | $6.89 | 14,218 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-06-15 | 2,610 | $55.93 | 11,608 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-06-15 | 3,295 | $56.88 | 8,313 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-06-15 | 3,095 | $58.04 | 5,218 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2015-06-15 | 9,000 | $0.00 | 9,000 | $6.89 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 157,000 | 2024-06-05 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.53 to $57.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.537 to $58.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 25% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
